Takeda
Takeda Pharmaceutical Company Limited, founded in 1781 and headquartered in Tokyo, Japan, is a leading research-based pharmaceutical company. It operates primarily in the pharmaceutical sector, focusing on five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which contribute to over 80% of its revenue. Takeda's diverse product portfolio includes established medications for conditions such as prostate cancer, peptic ulcers, hypertension, and diabetes. Additionally, Takeda Ventures, Inc., the company's venture capital arm, invests in therapeutic innovations across various stages of development, primarily in the United States, Canada, and Europe. The firm prioritizes investments in drug and biotherapeutic technologies, with a particular interest in cardiometabolic, central nervous system, chronic inflammatory, and oncology domains, while avoiding sectors like diagnostics and anti-infective products. In fiscal 2023, Takeda reported revenue of approximately JPY 4.3 trillion, with a significant portion generated from its operations in the US, Japan, and Europe.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.